To see all protocols that comply with the WHO Essential Medicine List 
Clinical safety note
Antineoplastic oral tablets and or capsules should not be broken or crushed. Crushing tablets carries exposure risks, and can alter the bioavailability of the drug.
If a patient is unable to swallow tablets or medication is being administered via a PEG tube or a nasogastric tube, then the pharmacist must be contacted for advice on alternative dose formulations.
If a patient vomits within a few hours of taking the drug do not repeat the dose. Inform the medical officer for further guidance.

This document provides information on the safe administration of oral antineoplastic drugs. Only health care professionals who have attained competency in safe administration, and handling and waste management of hazardous drugs (as per institutional guidelines) should perform this procedure.

This document should be read in conjunction with the safe handling of hazardous drugs document, and the safe administration of antineoplastic drugs document.

This document reflects what is currently regarded as safe practice. While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page


First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/450

26 May 2018